Clinical trial
Combined Antiinflammatory and Angiostatic Therapy in Patients With…
NCT00427999 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00427999 |
|---|---|
| Title | Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer |
| Official title | A Single Stage Phase II, Multi-centre, Open Label Study of Imatinib in Combination With Pioglitazone, Etoricoxib, Dexamethasone and Low-dose Treosulfane for Anti-inflammatory and Angiostatic Treatment in Patients With Hormone-refractory Prostate Cancer |
| Acronym | INV342 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | imatinib mesylate, Treosulfane, etoricoxib, pioglitazone, dexamethasone |
| Enrollment | 67 |
| Start date | Feb 1, 2007 |
| Primary completion | Jun 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Jan 29, 2007 |
| Last update posted | Nov 21, 2016 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: